Advertisement

Colitis pp 243-250 | Cite as

The Role of Biopsies in the Treatment of Colitis: Scoring of Disease Activity

  • Rish K. Pai
  • Karel Geboes
Chapter

Abstract

The development of new medications leads to a better disease control and clinical remission. Many clinical trials are usually needed before a new therapy can be released. The aim of clinical trials is to show efficacy and safety of the drug by defining different endpoints such as clinical and endoscopic remission and by registration of adverse events. Histology is one of the elements used in clinical trials for the assessment of the efficacy of a drug, most often as a secondary endpoint. For this purpose, scoring systems for both ulcerative colitis (UC) and Crohn’s disease (CD) have been developed for the measurement of disease activity. They usually rely on a combination of histological features. While they are not designed for routine practice, the underlying concepts may be useful in daily practice as numerous recent studies have shown the power of histologic disease activity to predict relapse and long-term outcomes.

Keywords

Clinical trials Score Disease activity Mucosal healing IBD 

References

  1. 1.
    Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–38.CrossRefPubMedGoogle Scholar
  2. 2.
    Ulcerative colitis: clinical trial endpoints guidance for industry - UCM515143.pdf [Internet]. [cited 2017 Mar 15]. Available from: https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM515143.pdf.
  3. 3.
    Bessissow T, Lemmens B, Ferrante M, Bisschops R, Van Steen K, Geboes K, et al. Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing. Am J Gastroenterol. 2012;107(11):1684–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Lemmens B, Arijs I, Van Assche G, Sagaert X, Geboes K, Ferrante M, et al. Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis. Inflamm Bowel Dis. 2013;19(6):1194–201.CrossRefPubMedGoogle Scholar
  5. 5.
    Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, et al. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. J Crohns Colitis. 2013;7(9):730–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis. 1966;11(11):847–57.CrossRefPubMedGoogle Scholar
  7. 7.
    Bryant RV, Burger DC, Delo J, Walsh AJ, Thomas S, von Herbay A, et al. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up. Gut. 2016;65(3):408–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Park S, Abdi T, Gentry M, Laine L. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2016;111(12):1692–701.CrossRefPubMedGoogle Scholar
  9. 9.
    Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120(1):13–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Zenlea T, Yee EU, Rosenberg L, Boyle M, Nanda KS, Wolf JL, et al. Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study. Am J Gastroenterol. 2016;111(5):685–90.CrossRefPubMedGoogle Scholar
  11. 11.
    Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133(4):1099–105. quiz 1340-1341CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Korelitz BI, Sultan K, Kothari M, Arapos L, Schneider J, Panagopoulos G. Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. World J Gastroenterol. 2014;20(17):4980–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Brennan GT, Melton SD, Spechler SJ, Feagins LA. Clinical implications of histologic abnormalities in Ileocolonic biopsies of patients with Crohn’s disease in remission. J Clin Gastroenterol. 2017;51(1):43–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Christensen B, Hanauer SB, Erlich J, Kassim O, Gibson PR, Turner JR, et al. Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes. Clin Gastroenterol Hepatol. 2017;15(10):1557–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011;17(3):194–8.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mosli MH, Parker CE, Nelson SA, Baker KA, MacDonald JK, Zou GY, et al. Histologic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2017;5:CD011256.PubMedGoogle Scholar
  18. 18.
    Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47(3):404–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mosli MH, Feagan BG, Zou G, Sandborn WJ, D’Haens G, Khanna R, et al. Development and validation of a histological index for UC. Gut. 2017;66(1):50–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, Bastien C, Cahn V, Cadiot G, et al. Development and validation of the Nancy histological index for UC. Gut. 2017;66(1):43–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Marchal-Bressenot A, Scherl A, Salleron J, Peyrin-Biroulet L. A practical guide to assess the Nancy histological index for UC. Gut. 2016;65(11):1919–20.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, et al. Histologic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database Syst Rev. 2017;7:CD012351.PubMedGoogle Scholar
  23. 23.
    D’Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114(2):262–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Naini BV, Cortina G. A histopathologic scoring system as a tool for standardized reporting of chronic (ileo)colitis and independent risk assessment for inflammatory bowel disease. Hum Pathol. 2012;43(12):2187–96.CrossRefPubMedGoogle Scholar
  25. 25.
    Villanacci V, Antonelli E, Geboes K, Casella G, Bassotti G. Histological healing in inflammatory bowel disease: a still unfulfilled promise. World J Gastroenterol. 2013;19:968–78.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Mayo Clinic ArizonaScottsdaleUSA
  2. 2.Department of PathologyGhent University HospitalGhentBelgium
  3. 3.Department of PathologyKU LeuvenLeuvenBelgium

Personalised recommendations